Table 1. Summary of Trials Used.
| Trial | Number of Pts Enrolled |
Women N (%) |
Men N (%) |
Type of ACS evaluated |
Intervention |
|---|---|---|---|---|---|
| GUSTO I 25 (1993) |
41,021 | 10,315 (25.2) |
30,653 (74.8) |
STEMI | t-PA; Sk + IV heparin; Sk + t- PA; Sk + SQ; Heparin; Hirudin |
| GUSTO IIb26 (1996) |
12,142 | 3,661 (30.2) |
8,479 (69.8) |
STEMI, NSTEMI, UA |
Heparin; Hirudin |
| GUSTO III27 (1997) |
15,059 | 4,124 (27.4) |
10,935 (72.6) |
STEMI | t-PA; r-PA |
| ASSENT II29 (1999) |
17,005 | 3,930 (23.1) |
13,074 (76.9) |
STEMI | t-PA; TNK |
| ASSENT III30 (2001) |
6,116 | 1,438 (23.5) |
4,678 (76.5) |
STEMI | Full-dose TNK + Heparin; Full-dose TNK + Enoxaparin; Half-dose TNK + Abciximab |
| ASSENT III+34 (2003) |
1,639 | 378 (23.1) |
1,261 (76.9) |
STEMI | Full-dose TNK + Heparin; Full-dose TNK + Enoxaparin |
| HERO 235 (2001) |
17,089 | 4,850 (28.4) |
12,237 (71.6) |
STEMI | Bivalirudin; Heparin; Sk |
| PURSUIT31 (2000) |
10,948 | 3,857 (35.2) |
7,090 (64.8) |
NSTEM, UA | Placebo; Low-dose Eptifibatide; High-dose Eptifibatide |
| PARAGON A28 (1998) |
2,282 | 776 (34.3) |
1,486 (65.7) |
NSTEMI, UA | Low-dose Lamifiban with and without Heparin; High doseLamifiban with and without Heparin |
| PARAGON B32 (2000) |
5,225 | 1,789 (34.2) |
3436 (65.8) |
NSTEMI, UA | Lamifiban; Heparin |
| GUSTO IV33 (2001) |
7,800 | 2,930 (37.6) |
4,870 (62.4) |
NSTEMI, UA | Heparin; 24 hour Abciximab; 48 hour Abciximab |
| Total | 136,247 |
38,048 (27.9) |
98,199 (72.1) |
Abbreviations: ACS, acute coronary syndromes; STEMI, ST segment elevation myocardial infarction; NSTEMI, non-STEMI; UA, unstable angina; t-PA, tissue plasminogen activator; Sk, streptokinase; TNK, tenecteplase.